cntx-6970
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 14, 2017 (NCT03787004)
Timeline
Indications
Mechanism of action
- C-C chemokine receptor type 2ANTAGONIST
CCR2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05025787 | Phase 2 | Oct 25, 2021 | Harvard University |
| NCT03787004 | Phase 1 | Aug 14, 2017 | Centrexion Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Centrexion Therapeutics | For profit | 1 | 1 | 1 | 2017 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1